FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Только для исследовательских целей. Полный disclaimer →

Исследования/Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Назад в Научную Библиотеку
GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.

May 16, 2026
Share

Исходная статья

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al.Drug design, development and therapy2025
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья разбивает выводы из исходной статьи выше на доступный язык для сообщества исследований Peptide. Наша цель — подчеркнуть то, что наиболее важно — практические последствия, надежность доказательств и то, что это означает для текущих исследований.

GLP-1 Receptor Agonists: Advancements in Pharmacokinetics and Drug Interactions

Published: May 16, 2026 | Source: Drug design, development and therapy (2025) | Category: GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide

Overview

A recent comprehensive review published in Drug Design, Development and Therapy provides critical insights into the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists (GLP-1 RAs) and a dual GLP-1/GIP receptor agonist. This study highlights how structural modifications to these peptides extend their half-life but may also increase the risk of adverse events, impacting clinical use in treating type 2 diabetes and obesity.

Study Background

GLP-1 RAs were initially developed to treat type 2 diabetes by mimicking the effects of natural GLP-1. However, native human GLP-1 has a very short half-life (approximately 2 minutes), necessitating structural modifications such as amino acid sequence changes, fatty acid conjugation, and fusion with albumin or Fc regions to enhance their therapeutic utility. The introduction of tirzepatide, which targets both GLP-1 and GIP receptors, further expanded the potential for these peptides in managing obesity.

What the Research Found

The review examines four approved GLP-1 RAs—exenatide, liraglutide, dulaglutide, and semaglutide—and tirzepatide. Key findings include:

  • Pharmacokinetics: Structural modifications have led to minimal metabolism and renal excretion for these peptides, resulting in prolonged half-lives compared to native GLP-1.
  • Drug-Drug Interactions (DDIs): Clinically significant DDIs mediated by drug-metabolizing enzymes or transporters are rare. However, mechanism-of-action-mediated DDIs involving delayed gastric emptying have been noted but generally considered clinically insignificant.
  • Specific Drug Interactions: Significant changes in exposure were observed for oral contraceptives and levothyroxine with the use of tirzepatide and semaglutide, respectively.

What This Means for Peptide Users

Clinicians need to be aware that while structural modifications have greatly improved the efficacy and convenience of GLP-1 RAs by extending their half-lives, they may also introduce new risks. For instance, patients taking oral contraceptives or levothyroxine should be closely monitored when using tirzepatide or semaglutide due to potential changes in drug exposure.

Limitations and Caveats

The review highlights several limitations:

  • Lack of Clinical Data: There is a dearth of clinical data on DDIs mediated by drug-metabolizing enzymes and transporters.
  • Volume of Distribution and Clearance Alterations: Further research is needed to understand how other mechanisms of action, such as changes in fat mass or cytochrome P450 activity, affect the pharmacokinetics of these peptides.

How This Compares to Previous Research

Previous studies have focused on individual GLP-1 RAs but lacked a comprehensive review that includes both pharmacokinetic profiles and DDIs. This study provides a consolidated view, making it easier for clinicians to understand the broader implications of using these therapies.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the current state of GLP-1 RAs and tirzepatide, there is still room for more detailed clinical studies on DDIs. The findings underscore the importance of personalized medicine approaches when prescribing these agents to ensure optimal safety and efficacy.

Key Takeaways

  • Structural Modifications: Enhance therapeutic utility but may increase adverse event risk.
  • DDI Monitoring: Clinicians should closely monitor patients using oral contraceptives or levothyroxine with tirzepatide or semaglutide.
  • Further Research Needed: Detailed clinical studies on DDIs and the impact of other mechanisms of action are essential.

Original Source

Citation: Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. DOI: 10.2147/DDDT.S506957

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был подготовлен командой исследований Peptide Contacts. Мы призываем читателей проверить полный исходный источник полная методология и данные. Исходное издание доступно на PubMed.

Связанные Исследования

Comments

Sign in to join the discussion

Этот анализ сгенерирован на основе рецензированных исследований для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.